

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

BIOSTIME

Biostime International Holdings Limited
合生元國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1112)

Matters in relation to the Administrative Punishment Decision Received by a Subsidiary of the Group And Resumption of Trading

The board of directors (the “**Board**”) of Biostime International Holdings Limited (the “**Company**”) and together with its subsidiaries, collectively referred to as the “**Group**”) wishes to advise the shareholders and potential investors of the Company of the following:

Reference is made to the announcements made by the Company on 27 June 2013, 9 July 2013 and 23 July 2013 (the “**Announcements**”), in relation to an administrative investigation (the “**Investigation**”) into a subsidiary of the Company. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as ascribed to them in the Announcements.

On 6 August 2013, BiosTime, Inc. (Guangzhou) (廣州市合生元生物製品有限公司, “**Biostime Guangzhou**”), a wholly-owned subsidiary of the Company, received an Administrative Punishment Decision (the “**Decision**”) issued by the National Development and Reform Commission of the People’s Republic of China (the “**NDRC**”). According to the Decision, the NDRC determined that Biostime Guangzhou violated Article 14 of Anti-Monopoly Law of the People's Republic of China (the “**PRC AML**”) by providing fixed prices for its products in its distribution agreements with its distributors, and therefore shall be subject to a fine in the amount of RMB162,900,000 according to Article 46 of the PRC AML. Biostime Guangzhou has decided not to make an application for an administrative reconsideration or to initiate administrative litigation, and it shall comply with the punishment imposed by the NDRC under the Decision by paying the above-mentioned amount of fine in a timely manner and shall continue to improve its internal control system to ensure that its various business decisions comply with the applicable PRC laws and regulations.

This announcement is made by our Company pursuant to the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

At the request of the Board of the Company, trading in the shares of the Company on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) have been halted with effect from 10:14 a.m. on Tuesday, 6 August 2013 pending the release of this announcement.

Application has been made to the Stock Exchange for the resumption of trading of the shares of the Company on the Stock Exchange with effect from 9:00 a.m. on Wednesday, 7 August 2013.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Biostime International Holdings Limited
Luo Fei
Chairman

Hong Kong, 7 August 2013

As at the date of this announcement, the executive Directors of the Company are Mr. Luo Fei and Ms. Kong Qingjuan; the non-executive Directors of the Company are Dr. Zhang Wenhui, Mr. Wu Xiong, Mr. Luo Yun and Mr. Chen Fufang; and the independent non-executive Directors of the Company are Dr. Ngai Wai Fung, Mr. Tan Wee Seng and Professor Xiao Baichun.